Hepatic steatosis after islet transplantation: Can ultrasound predict the clinical outcome? A longitudinal study in 108 patients

Massimo Venturini, Paola Maffi, Giulia Querques, Giulia Agostini, Lorenzo Piemonti, Sandro Sironi, Francesco De Cobelli, Paolo Fiorina, Antonio Secchi, Alessandro Del Maschio

Research output: Contribution to journalArticle

7 Citations (Scopus)

Abstract

Percutaneous intra-portal islet transplantation (PIPIT) is a less invasive, safer, and repeatable therapeutic option for brittle type 1 diabetes, compared to surgical pancreas transplantation. Hepatic steatosis is a consequence of the islet engraftment but it is curiously present in a limited number of patients and its meaning is controversial. The aims of this study were to assess hepatic steatosis at ultrasound (US) after PIPIT investigating its relationship with graft function and its role in predicting the clinical outcome. From 1996 to 2012, 108 patients underwent PIPIT: 83 type-1 diabetic patients underwent allo-transplantation, 25 auto-transplantation. US was performed at baseline, 6, 12, and 24 months, recording steatosis prevalence, first detection, duration, and distribution. Contemporaneously, steatotic and non-steatotic patients were compared for the following parameters: infused islet mass, insulin independence rate, β-score, C-peptide, glycated hemoglobin, exogenous insulin requirement, and fasting plasma glucose. Steatosis at US was detected in 21/108 patients, 20/83 allo-transplanted and 1/25 auto-transplanted, mostly at 6 and 12 months. Infused islet mass was significantly higher in steatotic than non-steatotic patients (IE/kg: S = 10.822; NS = 6138; p = 0.001). Metabolically, steatotic patients had worse basal conditions, but better islet function when steatosis was first detected, after which progressive islet exhaustion, along with steatosis disappearance, was observed. Conversely, in non-steatotic patients these parameters remained stable in time. Number of re-transplantations was significantly higher in steatotic than in non-steatotic patients (1.8 vs 1.1; p = 0.001). Steatosis at US seems to be related to the islet mass and local overworking activity. It precedes metabolic alterations and can predict graft dysfunction addressing to therapeutic decisions before islet exhaustion. If steatosis does not appear, no conclusion can be drawn.

Original languageEnglish
Pages (from-to)52-59
Number of pages8
JournalPharmacological Research
Volume98
DOIs
Publication statusPublished - Jun 12 2015

Fingerprint

Islets of Langerhans Transplantation
Longitudinal Studies
Liver
Transplantation
Insulin
Transplants
Pancreas Transplantation
C-Peptide
Glycosylated Hemoglobin A
Type 1 Diabetes Mellitus
Fasting
Glucose

Keywords

  • Hepatic steatosis
  • Islet transplantation
  • Pancreatogenic diabetes
  • Type 1 diabetes
  • Ultrasound
  • β-Score

ASJC Scopus subject areas

  • Pharmacology

Cite this

Hepatic steatosis after islet transplantation : Can ultrasound predict the clinical outcome? A longitudinal study in 108 patients. / Venturini, Massimo; Maffi, Paola; Querques, Giulia; Agostini, Giulia; Piemonti, Lorenzo; Sironi, Sandro; De Cobelli, Francesco; Fiorina, Paolo; Secchi, Antonio; Del Maschio, Alessandro.

In: Pharmacological Research, Vol. 98, 12.06.2015, p. 52-59.

Research output: Contribution to journalArticle

@article{36482f86c1b5458bbb3e5286ac068a30,
title = "Hepatic steatosis after islet transplantation: Can ultrasound predict the clinical outcome? A longitudinal study in 108 patients",
abstract = "Percutaneous intra-portal islet transplantation (PIPIT) is a less invasive, safer, and repeatable therapeutic option for brittle type 1 diabetes, compared to surgical pancreas transplantation. Hepatic steatosis is a consequence of the islet engraftment but it is curiously present in a limited number of patients and its meaning is controversial. The aims of this study were to assess hepatic steatosis at ultrasound (US) after PIPIT investigating its relationship with graft function and its role in predicting the clinical outcome. From 1996 to 2012, 108 patients underwent PIPIT: 83 type-1 diabetic patients underwent allo-transplantation, 25 auto-transplantation. US was performed at baseline, 6, 12, and 24 months, recording steatosis prevalence, first detection, duration, and distribution. Contemporaneously, steatotic and non-steatotic patients were compared for the following parameters: infused islet mass, insulin independence rate, β-score, C-peptide, glycated hemoglobin, exogenous insulin requirement, and fasting plasma glucose. Steatosis at US was detected in 21/108 patients, 20/83 allo-transplanted and 1/25 auto-transplanted, mostly at 6 and 12 months. Infused islet mass was significantly higher in steatotic than non-steatotic patients (IE/kg: S = 10.822; NS = 6138; p = 0.001). Metabolically, steatotic patients had worse basal conditions, but better islet function when steatosis was first detected, after which progressive islet exhaustion, along with steatosis disappearance, was observed. Conversely, in non-steatotic patients these parameters remained stable in time. Number of re-transplantations was significantly higher in steatotic than in non-steatotic patients (1.8 vs 1.1; p = 0.001). Steatosis at US seems to be related to the islet mass and local overworking activity. It precedes metabolic alterations and can predict graft dysfunction addressing to therapeutic decisions before islet exhaustion. If steatosis does not appear, no conclusion can be drawn.",
keywords = "Hepatic steatosis, Islet transplantation, Pancreatogenic diabetes, Type 1 diabetes, Ultrasound, β-Score",
author = "Massimo Venturini and Paola Maffi and Giulia Querques and Giulia Agostini and Lorenzo Piemonti and Sandro Sironi and {De Cobelli}, Francesco and Paolo Fiorina and Antonio Secchi and {Del Maschio}, Alessandro",
year = "2015",
month = "6",
day = "12",
doi = "10.1016/j.phrs.2015.03.002",
language = "English",
volume = "98",
pages = "52--59",
journal = "Pharmacological Research",
issn = "1043-6618",
publisher = "Academic Press",

}

TY - JOUR

T1 - Hepatic steatosis after islet transplantation

T2 - Can ultrasound predict the clinical outcome? A longitudinal study in 108 patients

AU - Venturini, Massimo

AU - Maffi, Paola

AU - Querques, Giulia

AU - Agostini, Giulia

AU - Piemonti, Lorenzo

AU - Sironi, Sandro

AU - De Cobelli, Francesco

AU - Fiorina, Paolo

AU - Secchi, Antonio

AU - Del Maschio, Alessandro

PY - 2015/6/12

Y1 - 2015/6/12

N2 - Percutaneous intra-portal islet transplantation (PIPIT) is a less invasive, safer, and repeatable therapeutic option for brittle type 1 diabetes, compared to surgical pancreas transplantation. Hepatic steatosis is a consequence of the islet engraftment but it is curiously present in a limited number of patients and its meaning is controversial. The aims of this study were to assess hepatic steatosis at ultrasound (US) after PIPIT investigating its relationship with graft function and its role in predicting the clinical outcome. From 1996 to 2012, 108 patients underwent PIPIT: 83 type-1 diabetic patients underwent allo-transplantation, 25 auto-transplantation. US was performed at baseline, 6, 12, and 24 months, recording steatosis prevalence, first detection, duration, and distribution. Contemporaneously, steatotic and non-steatotic patients were compared for the following parameters: infused islet mass, insulin independence rate, β-score, C-peptide, glycated hemoglobin, exogenous insulin requirement, and fasting plasma glucose. Steatosis at US was detected in 21/108 patients, 20/83 allo-transplanted and 1/25 auto-transplanted, mostly at 6 and 12 months. Infused islet mass was significantly higher in steatotic than non-steatotic patients (IE/kg: S = 10.822; NS = 6138; p = 0.001). Metabolically, steatotic patients had worse basal conditions, but better islet function when steatosis was first detected, after which progressive islet exhaustion, along with steatosis disappearance, was observed. Conversely, in non-steatotic patients these parameters remained stable in time. Number of re-transplantations was significantly higher in steatotic than in non-steatotic patients (1.8 vs 1.1; p = 0.001). Steatosis at US seems to be related to the islet mass and local overworking activity. It precedes metabolic alterations and can predict graft dysfunction addressing to therapeutic decisions before islet exhaustion. If steatosis does not appear, no conclusion can be drawn.

AB - Percutaneous intra-portal islet transplantation (PIPIT) is a less invasive, safer, and repeatable therapeutic option for brittle type 1 diabetes, compared to surgical pancreas transplantation. Hepatic steatosis is a consequence of the islet engraftment but it is curiously present in a limited number of patients and its meaning is controversial. The aims of this study were to assess hepatic steatosis at ultrasound (US) after PIPIT investigating its relationship with graft function and its role in predicting the clinical outcome. From 1996 to 2012, 108 patients underwent PIPIT: 83 type-1 diabetic patients underwent allo-transplantation, 25 auto-transplantation. US was performed at baseline, 6, 12, and 24 months, recording steatosis prevalence, first detection, duration, and distribution. Contemporaneously, steatotic and non-steatotic patients were compared for the following parameters: infused islet mass, insulin independence rate, β-score, C-peptide, glycated hemoglobin, exogenous insulin requirement, and fasting plasma glucose. Steatosis at US was detected in 21/108 patients, 20/83 allo-transplanted and 1/25 auto-transplanted, mostly at 6 and 12 months. Infused islet mass was significantly higher in steatotic than non-steatotic patients (IE/kg: S = 10.822; NS = 6138; p = 0.001). Metabolically, steatotic patients had worse basal conditions, but better islet function when steatosis was first detected, after which progressive islet exhaustion, along with steatosis disappearance, was observed. Conversely, in non-steatotic patients these parameters remained stable in time. Number of re-transplantations was significantly higher in steatotic than in non-steatotic patients (1.8 vs 1.1; p = 0.001). Steatosis at US seems to be related to the islet mass and local overworking activity. It precedes metabolic alterations and can predict graft dysfunction addressing to therapeutic decisions before islet exhaustion. If steatosis does not appear, no conclusion can be drawn.

KW - Hepatic steatosis

KW - Islet transplantation

KW - Pancreatogenic diabetes

KW - Type 1 diabetes

KW - Ultrasound

KW - β-Score

UR - http://www.scopus.com/inward/record.url?scp=84930760998&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84930760998&partnerID=8YFLogxK

U2 - 10.1016/j.phrs.2015.03.002

DO - 10.1016/j.phrs.2015.03.002

M3 - Article

C2 - 25814187

AN - SCOPUS:84930760998

VL - 98

SP - 52

EP - 59

JO - Pharmacological Research

JF - Pharmacological Research

SN - 1043-6618

ER -